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Neoadjuvant endocrine therapy given to patients
with large operable or locally advanced breast cancers
has the advantage that it can reduce tumour volumes
making inoperable tumours operable or patients who
would have required mastectomy suitable for breast-
conserving surgery. Early studies of patients treated se-
quentially in Edinburgh suggested that responses with
neoadjuvant aromatase inhibitors were superior to those
seen with tamoxifen (Table 1). It was also evident that
patients treated with tamoxifen had a lower rate of
conversion to breast-conserving surgery than those gi-
ven letrozole a subsequent randomised trial described
below.
Trial P024 compared four months of neoadjuvant
letrozle with tamoxifen in 324 patients and demon-
strated signiﬁcanty better clinical responses, ultrasound
Table 1
Median tumour volume reduction in series of patients with locally advanced breast cancer who received neoadjuvant endocrine therapy in the
Edinburgh Breast Unita
Agent Number of patients Patients with >50%
reduction, n (%)
Patients with <50% reduction
or <25% increase, n (%)
Patients with >25%
increase, n (%)
Tamoxifen 65 30 (46) 34 (52) 1 (2)
Letrozole 36 32 (89) 3 (8) 1 (3)
Anastrozole 23 18 (78) 5 (22) 0
Exemestane 12 10 (83) 2 (17) 0
a Tumour volume changes (reduction or increase) were assessed by ultrasound measurements during the 3-month treatment period.
Table 2
Primary and secondary eﬃcacy end-point results of trial P024 comparing 4 months of neoadjuvant letrozole versus tamoxifen (all study patients)
Eﬃcacy end-points Letrozole (n = 154) (%) Tamoxifen (n = 170) (%) P value
Primary end-point
Clinical response (palpation) 55 36 <0.001
Complete 10 4
Partial 45 32
Secondary end-points
Ultrasound response 35 25 0.042
Complete 3 1
Partial 32 24
Mammographic response 34 16 <0.001
Complete 4 0
Partial 30 16
Breast-conserving surgery 45 35 0.022
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reponses, mamographic responses and rates of conver-
ion to breast-conserving surgery with letrozle than for
tamoxifen treatment (Table 2). The major factor pre-
dicting response to aromatase inhibors is the oestrogen
receptor (ER) status. New data from Edinburgh conf-
irms our previous observations that the reponse rate, in
particular the median reducion in tumour volume, is
greater for ER 8 tumours than ER 6 and 7 tumours
when assessed using the ALLRED scale (Table 3). In
the P024 study patients with tumours which were ER or
PgR positive and were erbB1 or erbB2 positive were
signiﬁcantly more likely to respond to letrozole (88%)
than tamoxifen (21%), p ¼ 0:004. A recently completed
study (IMPACT) compared neoadjuvant anastrozole
alone, tamoxifen alone or the two combined in 330
postmenopausal women with ER-positive disease. The
results of this study were somewhat disappointng in
that the reponse rates in all three arms were similar.
The only end-point which was signiﬁcanty in favour of
anastrozole was the number of patients whose tumours
initially required mastectomy, but who subsequently
could be treated by breast-conserving surgery. Al-
though there was a suggestion in this study that pa-
tients whose tumours were erbB2-positive were more
likely to respond to anastrozole, the diﬀerence was not
signiﬁcant. What was evident in this study was that
there were biological diﬀerences between the drugs with
regard to their eﬀect on proliferation. By two weeks,
anastrozole reduced proliferation to a greater degree
than tamoxifen alone or the two agents combined.
These are important data and they mirror those of the
Anmidex, tamoxifen, alone or in combination (ATAC)
study. This study sugests that an analysis of biological
end-points two weeks after starting on the drug predicts
for long-term adjuvant eﬃcacy and warrants further
investigation.
Table 3
Comparing ER scores 8 vs. 6 and 7
ER score allred No. of Pts No. of responders % Response Median % reduction in tumour volume
Clin USS
8 60 48 80 76+ 67+
6 + 7 23 17 74 63 48
+P < 0.005 comparing ER scores 8 vs. 6 and 7.
ER, oestrogen receptor; Pts, patients; USS, ultrasound scan; Clin, clinical assessment.
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